The DOI matches its Crossref record.
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
Abstract
Objective: The α 4 β 7 integrin monoclonal antibody vedolizumab is hypothesised to be gut selective. Effects of vedolizumab on immune responses to parenterally or enterally administered antigens were investigated. Design: In this randomised, double-blind, placebo-controlled, phase I trial, healthy participants received a single intravenous dose of vedolizumab 750 mg (n=64) or placebo (n=63). After 4 days, participants began intramuscular hepatitis B vaccine (HBV; days 4, 32, 60) and oral cholera vaccine (OCV; days 4, 18) regimens. The study was designed to demonstrate a 15% non-inferiority margin for the between-group difference in the primary end point: percentage of participants with HBV seroconversion at day 74 (serum hepatitis B surface antigen (HBs) antibody titre ≥10 IU/L). OCV seroconversion at day 74 (>4-fold increase in serum cholera toxin (CT) antibodies) was a secondary end point. Results: A total of 56 (90.3%) placebo-treated and 54 (88.5%) vedolizumab-treated participants responded to HBV. Geometric mean anti-HBs titres were similar for placebo (114.4 IU/L) and vedolizumab (129.6 IU/L) at day 74. A total of 60 (96.8%) placebo-treated and 52 (82.5%) vedolizumab-treated participants responded to OCV at day 74. Geometric mean anti-CT IgG levels were higher for placebo than for vedolizumab at day 74 (9210.08 vs 3007.8 ELISA Units (EU)/mL) and day 32 (11629.3 vs 1575.4 EU/mL). Anti-CT IgA results were similar. Adverse events were consistent with previous experience. One serious adverse event (spontaneous abortion) was reported for placebo. Conclusions: Vedolizumab did not alter the response to parenterally administered antigens but reduced the response to oral antigens, demonstrating its gut-selective mechanism of action. Trial registration number: NCT Number: 01981616; EudraCT Number: 2011-001874-24.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
Current and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
Immunological pathogenesis of inflammatory bowel disease
Lee, S. H., Kwon, J. E., & Cho, M.-L. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.1.26 · Cited by 575
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Nakase, H., Uchino, M., Shinzaki, S., Matsuura, M., Matsuoka, K., Kobayashi, T., Saruta, M., Hirai, F., Hata, K., Hiraoka, S., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01784-1 · Cited by 505
Metadata
- Authors
- Wyant, T., Leach, T., Sankoh, S., Wang, Y., Paolino, J., Pasetti, M. F., Feagan, B. G., & Parikh, A.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2014-04-24
- Volume
- 64
- Issue
- 1
- Pages
- 77-83
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2102116540
- Cited by
- 177
- References
- 0
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. https://app.cochat.ai/papers/10.1136/gutjnl-2014-307127
- The paper
- Wyant, T., Leach, T., Sankoh, S., Wang, Y., Paolino, J., Pasetti, M. F., Feagan, B. G., & Parikh, A. (2015). Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. https://doi.org/10.1136/gutjnl-2014-307127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.